26
Sep
2019
Big IPO Week On Deck, Amazon & Walmart Health Moves, & Akcea Exec Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Sep
2019
Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Sep
2019
A Nonprofit That Carried a TB Drug Through the FDA: Bruce Carter on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Sep
2019
10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Sep
2019
Hot Job Market Creates Challenges for Companies, Opens Doors for Workers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Sep
2019
Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Sep
2019
Making a Difference for Sickle Cell Disease: Ted Love on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Sep
2019
Dr. Jekyll and Mr. Pharma-Bro: Coping With My Split Personality
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Aug
2019
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Aug
2019
Autoimmunity Research Paves the Way for New Ideas in Halting, Preventing Type 1 Diabetes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Aug
2019
BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Aug
2019
An Unforgettable Experience: The Kilimanjaro Climb to Fight Cancer Yearbook
The Kilimanjaro Climb to Fight Cancer was a marvelous experience. In every way. Weeks later, I’m still absorbing what it means to scientists at Fred Hutch, and to the biotech community. To start, consider the numbers: Our team of 27 climbers raised $1,587,475 for cancer research More than 2,200 donors contributed from around the country 33 sponsors supported the cause... Read More
20
Aug
2019
Getting in on the Ground Floor of the Biotech Boom: Joel Marcus on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2019
As CAR-T Ranks Expand, Industry Scrambles to Solve Long-Standing Manufacturing Challenges
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Aug
2019
Roche/Genentech’s Clever NTRK Strategy, Regeneron’s Ebola Win & PCR Pioneer Passes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Aug
2019
Executive Shortages Pose Challenge to Biotech Growth Prospects
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2019
Novartis’ No-No, Bayer Buys BlueRock, and Job Switches Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2019
From Pharma VC to Cell Therapy Startup: Janelle Anderson on The Long Run
Today’s guest on The Long Run is Janelle Anderson. Janelle is the chief strategy officer of Century Therapeutics. This is a company using induced pluripotent stem cells to make off-the-shelf cell therapies for cancer. This is the new dream of cell therapy, as scientists imagine ways to lower the cost and expand access for patients following the first wave of... Read More
23
Jul
2019
CRISPR Boosts Animal Models, Making Preclinical Research More Efficient
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2019
As Cancer Immunotherapy Booms, Biomarkers Re-Emerge to Guide Treatment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.